
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc. is engaged in developing cannabinoid-based formulations for conditions such as Alzheimer's disease, with investigational drug assets like IGC-AD1 demonstrating potential effectiveness in addressing critical aspects of the disease. The current valuation appears attractive, with analysts indicating a favorable outlook supported by a net present value (NPV) analysis that suggests significant upside from the existing share price. Furthermore, the anticipated positive data from ongoing studies is expected to serve as a catalyst for future stock performance, highlighting the company's growth potential in the healthcare market.
Bears say
IGC Pharma Inc reported a net loss of $1.6 million, translating to an earnings per share (EPS) of $(0.02), which aligns closely with prior estimates but raises concerns about ongoing financial instability. The company faces significant challenges related to its product candidates, including the risks of failing to demonstrate safety and efficacy during clinical trials and the potential inability to secure regulatory approvals for its investigational assets targeting Alzheimer's disease. Additionally, liquidity risks and external factors such as competition and shifting investor sentiments towards biotech stocks further contribute to the negative outlook on IGC Pharma's stock performance.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares